DAFTAR PUSTAKA

1. Harrison TR, Resnick WR, Wintrobe MM, Thorn GW, Adams RD, Beeson PB et al. Harrison's : principles of internal medicine 19th ed. Mc Graw Hill. 2015: 153, 803 – 813

2. Metlay JP, Waterer GW, Long AC, Anzueto A, Brozek J, Crothers K, et al. Diagnosis and treatment of adults with community-acquired pneumonia. American Journal of Respiratory and Critical Care Medicine. 2019 Oct 1;200(7):45 – 67

3. Burnham JP, Kollef MH. CAP, HCAP, HAP, VAP. Chest. 2017;152:909 – 10

4. Azmi S, Aljunid SM, Maimaiti N, Ali AA, Muhammad Nur A, de Rosas-Valera M, et al. Assessing the burden of pneumonia using administrative data from Malaysia, Indonesia, and the Philippines. International Journal of Infectious Diseases. 2016 Aug 1;49:87 – 93.

5. 2019 World Health Organization (WHO) Top 10 causes of death worldwide 2019. Can accsess https://www.who.int/en/news-room/fact-sheets/detail/the-top-10-causes-of-death.

6. Jain S, Self WH, Wunderink RG, Fakhran S, Balk R, Bramley AM, et al. Community-acquired pneumonia requiring hospitalization among U.S. adults. New England Journal of Medicine. 2015 Jul 30;373(5):415–27

7. Arnold FW, Wiemken TL, Peyrani P, Ramirez JA, Brock GN. Mortality differences among hospitalized patients with community-acquired pneumonia in three world regions: Results from the Community-Acquired Pneumonia Organization (CAPO) International Cohort Study. Respiratory Medicine. 2013 Jul;107(7):1101–11.

8. Badan Penelitian dan Pengembangan Kesehatan. Riset kesehatan dasar (RISKESDAS). Lap Nas 2018: 73 – 8.

9. Badan Penelitian dan Pengembangan Kesehatan. Riset kesehatan dasar (RISKESDAS). Laporan Provinsi Sumatera Barat 2018: 60 – 1

10. Laporan Rekam Medis. Padang: RSUP Dr. M. Djamil, Rekam Medis; 2021

11. Lim WS, Woodhead M. British Thoracic Society adult community acquired pneumonia audit 2009/10. Thorax. 2011;66(6):548–9

12. Lim WS, Baudouin S, George R, Hill A, Jamieson C, Jeune IL, et al. British Thoracic Society guidelines for the management of community acquired pneumonia in adults: Update 2009. Thorax. 2009;64(3):1 – 55

13. Lim WS, Rodrigo C, Turner AM, Welham S, Calvert JM. British Thoracic Society community-acquired pneumonia care bundle: Results of a national implementation project. Thorax. 2016 Mar 1;71(3):288–90

14. Karakioulaki M, Stolz D. Biomarkers and clinical scoring systems in community acquired pneumonia. Annals of Thoracic Medicine. 2018;14(3):165 – 72 .

15. Liu JL, Xu F, Zhou H, Wu XJ, Shi LX, Lu RQ, et al. Expanded CURB-65: A new score system predicts severity of community-acquired pneumonia with superior efficiency. Scientific Reports. 2016 Mar 18;6:1 – 6 .

16. Alavi-Moghaddam M, Bakhshi H, Rezaei B, Khashayar P. Pneumonia severity index compared to CURB-65 in predicting the outcome of community acquired pneumonia among patients referred to an Iranian emergency department: A prospective survey. Brazilian Journal of Infectious Diseases. 2013 Mar;17(2):179–83

17. Marrie TJ, Huang JQ. Admission is not always necessary for patients with community-acquired pneumonia in risk classes IV and V diagnosed in the emergency room. Can Respir J. 2007;14(4):212 – 6 .

18. Shehata SM, Sileem AE, Shahien NE. Prognostic values of pneumonia severity index, CURB-65 and expanded CURB-65 scores in community-acquired pneumonia in Zagazig University Hospitals. Egyptian Journal of Chest Diseases and Tuberculosis. 2017 Jul;66(3):549–55.

19. Efiyanti, Pitoyo CW, Singh G, Koesno S. Uji validasi Expanded CURB-65 sebagai prediktor mortalitas 30 hari pasien pneumonia komunitas di rumah sakit umum pusat nasional cipto mangunkusumo. Indonesian Journal Chest.2018;5(1)

20. Shaddock EJ. How and when to use common biomarkers in community-acquired pneumonia. Pneumonia. 2016 Dec;8(17):1 – 7.

21. Aloisio E, Dolci A, Panteghini M. Procalcitonin : Between evidence and critical issues. Clinica Chimica Acta. Elsevier B.V. 2019;496:7–12.

22. Guo S, Mao X, Liang M. The moderate predictive value of serial serum CRP and PCT levels for the prognosis of hospitalized community-acquired pneumonia. Respiratory Research. 2018 Oct 1;19(1):1 – 9.

23. Liu D, Su L, Han G, Yan P, Xie L. Prognostic value of procalcitonin in adult patients with sepsis : A systematic review and meta-analysis. PLoS ONE. 2015 Jun 15;10(6).

24. Sánchez FV, Méndez BV, Gutiérrez JFR, García ÁE, García MÁG. New role of biomarkers : Mid-regional pro-adrenomedullin, the biomarker of organ failure. Annals of Translational Medicine. 2016 August 24;4(17):1 – 11

25. Liu D, Xie L, Zhao H, Liu X, Cao J. Prognostic value of mid-regional pro-adrenomedullin (MR-proADM) in patients with community-acquired pneumonia : A systematic review and meta-analysis. BMC Infectious Diseases. 2016 May 26;16(1):1 – 11

26. Krüger S, Ewig S, Giersdorf S, Hartmann O, Suttorp N, Welte T, et al. Cardiovascular and inflammatory biomarkers to predict short- and long-term survival in community-acquired pneumonia : Results from the German Competence Network, CAPNETZ. American Journal of Respiratory and Critical Care Medicine. 2010 Dec 1;182(11):1426–34

27. Bello S, Lasierra AB, Mincholé E, Fandos S, Ruiz MA, Vera E, et al. Prognostic power of proadrenomedullin in community-acquired pneumonia is independent of aetiology. European Respiratory Journal. 2012 May 1;39(5):1144–55.

28. Grippi MA, Elias JA, Fishman JA, Kotloff RM, Pack AI, Senior RM et al. Acute bronchitis and community-acquired pneumonia in Fifth edition Fishman's Pulmonary disease and disorders. Mc Graw Hill Education. 2015; 702 – 810.

29. Ramirez JA, Wiemken TL, Peyrani P, Arnold FW, Kelley R, Mattingly WA, et al. Adults hospitalized with pneumonia in the United States:

Incidence, epidemiology, and mortality. Clinical Infectious Diseases. 2017 Dec 1;65(11):1806–12

30. Takaki M, Nakama T, Ishida M, Morimoto H, Nagasaki Y, Shiramizu R, et al. High incidence of community-ccquired pneumonia among rapidly aging population in Japan: A prospective hospital-based surveillance. Jpn. J. Infect. Dis. 2014;67:1 – 7.

31. Laporan Rekam Medis. Padang: RSUP Dr. M. Djamil, Rekam Medis; 2016.

32. Rider AC, Frazee BW. Community-acquired pneumonia. Emergency Medicine Clinics of North America. W.B. Saunders. 2018;36: 665–83

33. Mandell LA. Community-acquired pneumonia: An overview. Postgraduate Medicine. 2015 Jan 1;127(6):607–15

34. Perhimpunan Dokter Paru Indonesia (PDPI). Pneumonia komunitas : pedoman diagnosis dan tatalakasana di Indonesia. 2014.

35. Lutfiyya MN, Henley E, Chang LF, Wessel Reyburn S. Diagnosis and treatment of community-acquired pneumonia [Internet]. 2006. Available from: www.aafp.org/afp.

36. Moldoveanu B, Otmishi P, Jani P, Walker J, Sarmiento X, Guardiola J, et al. Inflammatory mechanisms in the lung. Journal of Inflammation Research. 2009;2:1 – 12

37. Chen L, Deng H, Cui H, Fang J, Zuo Z, Deng J, et al. Inflammatory responses and inflammation-associated diseases in organs. Oncotarget. 2018;9(6):7204-18 Available from : www.impactjournals.com/oncotarget/

38. Signore A. About inflammation and infection. EJNMMI Research. Springer. 2013;3(8):1–2

39. El-Benna J, Nedelec MH, Marzaioli V, Marie JC, Pocidalo MAG, Dang PMC et al. Priming of the neutrophil respiratory burst: role in host defense and inflammation. Immunological reviews. 2016;273:180 – 93

40. Abbas AK, Lichtman AH, Pillai S. Basic immunology : functions and disorders of the immune system 5th edition. Elsevier. 2016:27 – 53

41. Ozcelik F, Pence HH, Ozturkeri HY, Sertoğlu E. Adrenomedullin as a Protein with Multifunctional Behavior and Effects in Various Organs and

Tissues. International Journal of Negative Results. 2019 Apr 19;1(2):12–29

42. Eto T, Kato J, Kitamura K. Regulation of production and secretion of adrenomedullin in the cardiovascular system. Regulatory Peptides. 2003;112:61–9

43. Morgenthaler NG, Struck J, Alonso C, Bergmann A. Measurement of midregional proadrenomedullin in plasma with an immunoluminometric assay. Clinical Chemistry. 2005 Oct;51(10):1823–9

44. Pereira JM, Azevedo A, Basílio C, Sousa-Dias C, Mergulhão P, Paiva JA. Mid-regional proadrenomedullin : An early marker of response in critically ill patients with severe community-acquired pneumonia? Revista Portuguesa de Pneumologia (English Edition). 2016 Nov 1;22(6):308–14.

45. Lorubbio M, Conti AA, Ognibene A. Midregional pro-adrenomedullin (MR-ProADM) reference values in serum. Clinical Biochemistry. 2018; https://doi.org/10.1016/j.clinbiochem.2018.01.003

46. Piccioni A, Saviano A, Cicchinelli S, Valletta F, Santoro MC, de Cunzo T, et al. Proadrenomedullin in sepsis and septic shock : A role in the emergency department. Medicina. 2021;57(920):1 – 7

47. Garazzino S, Altieri E, Denina M. The Role of pro-adrenomedullin as a marker of severe Bacterial infection in children : A review. Reports. 2019 Jul 8;2(17):1 – 9.

48. Eisenhut M. A role for adrenomedullin in the pathogenesis of alveolar edema. Critical Care. 2006;10(4)1.

49. Sharma JN, Al-Omran A, Parvathy SS. Role of nitric oxide in inflammatory diseases. Inflammopharmacology. 2007;15(54):252–9

50. Huang DT, Angus DC, Kellum JA, Pugh NA, Weissfeld LA, Struck J, et al. Midregional proadrenomedullin as a prognostic tool in community-acquired pneumonia. Chest. 2009 Sep 1;136(3):823–31

51. Suberviola B, Castellanos-Ortega Á, Llorca J, Ortiz F, Iglesias D, Prieto B. Prognostic value of proadrenomedullin in severe sepsis and septic shock patients with community-acquired pneumonia. Swiss Medical Weekly. 2012 Mar;142:1 – 8.

52. Önal U, Valenzuela-Sánchez F, Vandana KE, Rello J. Mid-regional pro-adrenomedullin (Mr-proADM) as a biomarker for sepsis and septic shock : Narrative review. Healthcare (Switzerland) 2018;6:1 – 14.

53. Spoto S, Nobile E, Carnà EPR, Fogolari M, Caputo D, de Florio L, et al. Best diagnostic accuracy of sepsis combining SIRS criteria or qSOFA score with procalcitonin and mid-regional pro-adrenomedullin outside ICU. Scientific Reports. 2020 Dec 1;10(1):1 – 11.

54. Kato J, Kitamura K, Eto T. Plasma adrenomedullin level and development of hypertension. Journal of Human Hypertension. 2006 Aug;20(8):566–70.

55. Zhu L, Sui L, Wu S, Wang L, Fu J, Wang X. Association between essential hypertension and three vasoactive peptides, urotensin II, endothelin and adrenomedullin. Clinical and Experimental Hypertension. 2015 Oct 3;37(7):604–8.

56. Kato J, Kitamura K, Matsui E, Tanaka M, Ishizaka Y, Kita T, *et al*. Plasma adrenomedullin patients with essential and natriuretic peptides in or malignant hypertension. Hypertens Res. 1999;22(1):61 – 5.

57. Hu W, Zhou PH, Zhang X bin, Xu CG, Wang W. Plasma concentrations of adrenomedullin and natriuretic peptides in patients with essential hypertension. Experimental and Therapeutic Medicine. 2015 May 1;9(5):1901–8.

58. Rademaker MT, Cameron VA, Charles CJ, Lainchbury JG, Nicholls MG, Richards AM. Adrenomedullin and heart failure. Regulatory Peptides. Elsevier. 2003;112:51–60.

59. Nishikimi T, Nakagawa Y. Adrenomedullin as a biomarker of heart failure. Heart Failure Clinics. Elsevier Inc. 2018;14:49–55.

60. Nishikimi T, Saito Y, Kitamura K, Ishimitsu T, Eto T, Kangawa K, *et al*. Increased plasma levels of adrenomedullin in patients with heart failure. J Am Coil Cardiol. 1995;26(6):1424 – 31

61. Nishikimi T. Adrenomedullin in the kidney-renal physiological and pathophysiological roles. Current Medicinal Chemistry. 2007;14:1689–99

62. Dieplinger B, Mueller T, Kollerits B, Struck J, Ritz E, von Eckardstein A, et al. Pro-A-type natriuretic peptide and pro-adrenomedullin predict

progression of chronic kidney disease : The MMKD Study. Kidney International. 2009;75(4):408–14.

63. Czajkowska K, Zbroch E, Bielach-Bazyluk A, Mitrosz K, Bujno E, Kakareko K, et al. Mid-regional proadrenomedullin as a new biomarker of kidney and cardiovascular diseases—is it the future? Journal of Clinical Medicine. 2021;10:1–14.

64. Zudaire E, Martínez A, Cuttitta F. Adrenomedullin and cancer. Regulatory Peptides. Elsevier. 2003;112:175–83.

65. Ayu D, Setyaningrum W, Siregar NC, Tjahjadi H. Expression of adrenomedullin and its correlation with apoptotic and mitotic count in breast invasive cancer NST with or without lymph node metastasis. Asian Journal of Microbiology. 2015;17(2):1 – 7.

66. Aggarwal G, Ramachandran V, Javeed N, Arumugam T, Dutta S, Klee GG, et al. Adrenomedullin is up-regulated in patients with pancreatic cancer and causes insulin resistance in β cells and mice. Gastroenterology. 2012;143(6):1510 – 17.

67. Lim WS, van der Eerden MM, Laing R, Boersma WG, Karalus N, Town GI, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax. 2003;58:377 – 82.

68. Drent M, Cobben NAM, Henderson RF, Wouters EFM, van Dieijen-Visser M. Usefulness of lactate dehydrogenase and its isoenzymes as indicators of lung damage or inflammation. European Respiratory Journal. European Respiratory Society. 1996;9;1736–42.

69. Ewig S, Bauer T, Hasper E, Pizzulli L, Kubini R, Luderitz B. Prognostic analysis and predictive rule for outcome of hospital-treated community-acquired pneumonia. European Respiratory Journal. 1995;8:392–7.

70. Hendy RM, Elawady MA, el Kareem HMA. Role of lactate dehydrogenase and other biomarkers in predicting prognosis of community-acquired pneumonia. Egyptian Journal of Bronchology. 2019 Dec;13(4):539–44

71. Suyastri, Medison I, Herman D, Russilawati. Perbandingan Expanded CURB-65 terhadap CURB-65 dan PSI dalam memprediksi luaran pasien pneumonia komunitas. Journal Endurance. 2019; 4(3):608 – 16.

72. Montrucchio G, Sales G, Rumbolo F, Palmesino F, Fanelli V, Urbino R et al. Effectiveness of mid-regional proadrenomedullin (MR-proADM) as prognostic marker in COVID-19 critically ill patients: An observational prospective study. Plos One. 2021;1 – 14.

73. Christ-Crain M, Morgenthaler NG, Stolz D, Muller C, Bingisser R, Harbarth S et al. Pro-adrenomedullin to predict severity and outcome in community-acquired pneumonia. Critical Care 2006;10(3):1 – 8

74. Septiandry, Adeputra (2021) Korelasi Antara Kadar Soluble Triggering Receptor Expressed On Myeloid Cells-1 (sTREM-1) Sputum Dengan Skor Expanded CURB-65 Pada Pasien Pneumonia Komunitas. Masters thesis, Universitas Andalas.

75. Silveyra P, Fuentes N, Rivera L. Understanding the intersection of environmental pollution, pneumonia, and inflammation : Does gender play a role?. Contemporary Topics of Pneumonia. 2017. doi:10.5772/intechopen.69627.

76. Quero BG, Fernandez LS, Moyano MG, Garrido IS, Bonilla AG, Crespo BG et al. Difference in community acquired pneumonia according gender. European Respiratoy Journal. 2017. 50:PA4101

77. Chebib N, Cuvelier C, Maleziux-Picard A, Parent T, Roux X, Fassier T et al. Pneumonia prevention in the elderly patients : the other sides. Aging Clinical and Experimental Research. 2019 https://doi.org/10.1007/s40520-019-01437-7.

78. Riccioni G, Di Pietro V, Staniscia T, De Feudis L, Traisci G, Capani F et al. Communityacquired pneumonia in internal medicine: A one-year retrospective study based on pneumonia severity index. Internationl Journal of Immunopathology and Pharmacology. 2005;18(3):575 – 86.

79. Vazquez EG, Soto S, Hernadez-Torres A, Herrero JA, Gomez J. Description of a cohort of low-risk patients with community-acquired

pneumonia admitted to a university hospital. Emergencias. 2010;22:275–81.

80. Lee JH, Kim J, Kim K, Jo YH, Rhee JE, Kim TY et al. Albumin and C-reactive protein have prognostic significance in patients with community-acquired pneumonia. Journal of Critical Care. 2011;26:287 – 94

81. Adnan M, Hasmat N, Rahat T, Burki A. Prognostic value of five serum markers predicting in-hospital mortality amongs adult with community acquired pneumonia. Journal of Infection in Developing Countries. 2022;16(1):166 – 72.

82. Zao L, Bao J, Shang Y, Yin L, Yu Y, Xie Y et al. The prognostic value of serum albumin levels and respiratory rate for community-acquired pneumonia: A prospective, multi-center study. PLoS ONE 16(3): e0248002. https://doi.org/10.1371/journal.pone.0248002

83. El-Maraghy AA, Abdel-Fattah EB, Ahmed MS. Platelet count: Is it a possible marker for severity and outcome of community acquired pneumonia?. Egyptian Journal of Chest Diseases and Tuberculosis. 2016;65:499–504

84. Ghoenim AHA, Mohammad MA, Elghamrawy MA, Embarak S. Platelet count as a predictor of outcome of hospitalized patients with communityacquired pneumonia at Zagazig University Hospitals, Egypt. The Egyptian Journal of Bronchology. 2020;14(11):1 – 7.

85. Kolditz M, Halank M, Schulte-Hubbert B, Bergmann S, Albrecht S, Hoffken G. Copeptin predicts clinical deterioration and persistent instability in community-acquired pneumonia. Respiratory Medicine. 2012;106:1320 – 8

86. Courtais C, Kuster N, Dupuy AM, Folschveiller M, Jreige R, Bargnoux AS et al. Proadrenomedullin, a useful tool for risk stratification in high Pneumonia Severity Index score community acquired pneumonia. American Journal of Emergency Medicine. 2013;31:215 – 221

87. Al-Shuaibi M, Bahu RR, Chaftari AM, Al-Wohoush I, Shomali W, Jiang Y et al. Pro-adrenomedullin as a novel biomarker for predicting infections

and response to antimicrobials in febrile patients with hematologic malignancies. Clinical Infectious Diseases. 2013;56(7):943 – 50.

88. Angeletti S, Spoto S, Fogolari M, Cortogiani M, Fioravanti M, De-Florio L et al. Diagnostic and prognostic role of procalcitonin and MR-proAdrenomedullin in bacterial infection. APMIS. 2015;123:740 – 8.